Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients-Reference-Cited by-同舟云学术

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients

Published:2017-02 Issue:1 Volume:58 Page:40-48
ISSN:0353-9504
Container-title:Croatian Medical Journal
language:
Short-container-title:Croat Med J

Author:

Pejša Vlatko,Prka Željko,Lucijanić Marko,Mitrović Zdravko,Piršić Mario,Jakšić Ozren,Ajduković Radmila,Kušec Rajko

Publisher

Croatian Medical Journals

Subject

General Medicine

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose‐adjusted EPOCH and rituximab (DA‐EPOCH‐R) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem);European Journal of Haematology;2023-04-02

2. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis;Clinical Lymphoma Myeloma and Leukemia;2022-10

3. Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes;Leukemia & Lymphoma;2022-02-02

4. No Evident Prognostic Benefit of Statin Use in Diffuse Large B-Cell Lymphoma Patients with Unfavorable Disease Features Treated with R-DA-EPOCH;Pharmacology;2022

5. Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience;Cancer Cell International;2021-09-17